Literature DB >> 16987895

Effect of verteporfin photodynamic therapy on endostatin and angiogenesis in human choroidal neovascular membranes.

Olcay Tatar1, Kei Shinoda, Annemarie Adam, Tillmann Eckert, Claus Eckardt, Klaus Lucke, Christoph Deuter, Karl Ulrich Bartz-Schmidt, Salvatore Grisanti.   

Abstract

AIM: To evaluate the effect of verteporfin photodynamic therapy (PDT) on endostatin with regard to expression of vascular endothelial growth factor (VEGF) in human choroidal neovascular membranes (CNVs) secondary to age-related macular degeneration.
METHODS: A retrospective review of an interventional case series of 68 patients who underwent removal of CNV. 29 patients were treated with PDT 3-655 days before surgery. 39 CNVs without previous treatment were used as controls. CNVs were stained for CD34, CD105, Ki-67, cytokeratin 18, endostatin, E-selectin and VEGF. "Predominance score of VEGF over endostatin" (mean) was defined as the difference between VEGF and endostatin staining scores.
RESULTS: In four CNVs treated by PDT 3 days previously, PS was significantly higher in the retinal pigment epithelium (mean = 2.5, p = 0.006) and stroma (mean = 2, p = 0.015) than in the control group (mean = 0). At longer post-PDT intervals, PS was significantly decreased in the retinal pigment epithelium (mean = 0, p = 0.019) and stroma (mean = 0, p = 0.015). Proliferative activity was high (p = 0.023), but mostly related to inflammatory cells. PDT did not influence E-selectin expression significantly.
CONCLUSIONS: VEGF predominance over endostatin early after PDT might contribute to enhanced angiogenic activity associated with recurrences. Strategies upregulating or replacing endostatin early after PDT might increase the effectiveness of PDT.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16987895      PMCID: PMC1857619          DOI: 10.1136/bjo.2006.105288

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  59 in total

Review 1.  Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration.

Authors:  U Schmidt-Erfurth; T Hasan
Journal:  Surv Ophthalmol       Date:  2000 Nov-Dec       Impact factor: 6.048

2.  Active drug targeting with immunoconjugates to choroidal neovascularization.

Authors:  T Yasukawa; H Kimura; Y Tabata; H Miyamoto; Y Honda; Y Ikada; Y Ogura
Journal:  Curr Eye Res       Date:  2000-12       Impact factor: 2.424

3.  Generation and degradation of human endostatin proteins by various proteinases.

Authors:  M Ferreras; U Felbor; T Lenhard; B R Olsen; J Delaissé
Journal:  FEBS Lett       Date:  2000-12-15       Impact factor: 4.124

Review 4.  Collagen XVIII/endostatin structure and functional role in angiogenesis.

Authors:  U K Zatterstrom; U Felbor; N Fukai; B R Olsen
Journal:  Cell Struct Funct       Date:  2000-04       Impact factor: 2.212

5.  Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization.

Authors:  K Spilsbury; K L Garrett; W Y Shen; I J Constable; P E Rakoczy
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

6.  Choroidal neovascularization in the rat induced by adenovirus mediated expression of vascular endothelial growth factor.

Authors:  J Baffi; G Byrnes; C C Chan; K G Csaky
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-10       Impact factor: 4.799

7.  VEGF is major stimulator in model of choroidal neovascularization.

Authors:  N Kwak; N Okamoto; J M Wood; P A Campochiaro
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-09       Impact factor: 4.799

8.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.

Authors: 
Journal:  Am J Ophthalmol       Date:  2001-05       Impact factor: 5.258

9.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.

Authors:  N M Bressler
Journal:  Arch Ophthalmol       Date:  2001-02

10.  Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen.

Authors:  D T Shima; A P Adamis; N Ferrara; K T Yeo; T K Yeo; R Allende; J Folkman; P A D'Amore
Journal:  Mol Med       Date:  1995-01       Impact factor: 6.354

View more
  10 in total

1.  Polymorphisms in the VEGF-A in polypoidal choroidal vasculopathy in a Korean population.

Authors:  Dong Ho Park; In Taek Kim
Journal:  Jpn J Ophthalmol       Date:  2012-02-04       Impact factor: 2.447

2.  Towards a rational approach to combination therapy for neovascular age-related macular degeneration.

Authors:  Jorge G Arroyo
Journal:  Br J Ophthalmol       Date:  2007-02       Impact factor: 4.638

3.  Matrix metalloproteinases in human choroidal neovascular membranes excised following verteporfin photodynamic therapy.

Authors:  Olcay Tatar; Annemarie Adam; Kei Shinoda; Tillmann Eckert; Gábor B Scharioth; Micheal Klein; Efdal Yoeruek; Karl Ulrich Bartz-Schmidt; Salvatore Grisanti
Journal:  Br J Ophthalmol       Date:  2007-05-02       Impact factor: 4.638

4.  Combination therapy for choroidal neovascularisation.

Authors:  Albert J Augustin; Indre Offermann
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

5.  Choroidal morphology and short-term outcomes of combination photodynamic therapy in polypoidal choroidal vasculopathy.

Authors:  Jiwon Baek; Jae Hyung Lee; Sohee Jeon; Won Ki Lee
Journal:  Eye (Lond)       Date:  2018-10-10       Impact factor: 3.775

Review 6.  Polypoidal Choroidal Vasculopathy in Asians.

Authors:  Chee Wai Wong; Tien Y Wong; Chui Ming Gemmy Cheung
Journal:  J Clin Med       Date:  2015-04-24       Impact factor: 4.241

7.  Incidence, outcomes, and risk factors for hemorrhagic complications in eyes with polypoidal choroidal vasculopathy following photodynamic therapy in Indian subjects.

Authors:  Pukhraj Rishi; Ekta Rishi; Minal Sharma; Aditya Maitray; Muna Bhende; Lingam Gopal; Tarun Sharma; Dhanashree Ratra; Parveen Sen; Pramod Bhende; Chetan Rao; Pradeep Susvar
Journal:  Indian J Ophthalmol       Date:  2017-08       Impact factor: 1.848

Review 8.  Polypoidal choroidal vasculopathy: An update on current management and review of literature.

Authors:  Amit Harishchandra Palkar; Vikas Khetan
Journal:  Taiwan J Ophthalmol       Date:  2019 Apr-Jun

9.  Histone deacetylase inhibitor attenuates experimental fungal keratitis in mice.

Authors:  Xiaohua Li; Min Yuan; Ruijie Yin; Xiaohui Liu; Yu Zhang; Shengtao Sun; Lei Han; Shikun He
Journal:  Sci Rep       Date:  2019-07-08       Impact factor: 4.379

10.  Polypoidal Choroidal Vasculopathy.

Authors:  Joon-Bom Kim; Rajinder S Nirwan; Ajay E Kuriyan
Journal:  Curr Ophthalmol Rep       Date:  2017-04-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.